Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program, PMID: 32445184
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial, PMID: 24814090
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?, PMID: 31951748
Etrolizumab for ulcerative colitis: the new kid on the block?, PMID: 26914639
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease, PMID: 30774593
Antibodies to watch in 2020, PMID: 31847708
Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease, PMID: 29601644
Etrolizumab for induction of remission in ulcerative colitis, PMID: 26630451
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes, PMID: 27366219
Biologic agents for IBD: practical insights, PMID: 26284562
New treatment options for inflammatory bowel diseases, PMID: 29556726
Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison, PMID: 30395950
Anti-integrin therapy for inflammatory bowel disease, PMID: 29740202
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances, PMID: 31127023
α 4 β 7 integrin inhibitors: a patent review, PMID: 30444683
Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis, PMID: 29178491
Etrolizumab in moderate-to-severe ulcerative colitis, PMID: 24814088
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis, PMID: 26522261
AlphaE Expression in Inflammatory Bowel Disease: a Biomarker for the use of Etrolizumab?, PMID: 30418517
Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa, PMID: 25457851
Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s, PMID: 29788362
Etrolizumab: anti-β7-a novel therapy for ulcerative colitis, PMID: 24269566
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis, PMID: 22717454
Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers, PMID: 33778929
An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers, PMID: 33778928
Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis, PMID: 30478492
Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis, PMID: 26412221
Next-Generation Therapeutics for IBD, PMID: 26031830
Next-Generation Therapeutics for Inflammatory Bowel Disease, PMID: 27461274
Anti-trafficking agents in the treatment of inflammatory bowel disease, PMID: 31567498
Emerging Therapies for Inflammatory Bowel Disease, PMID: 30374806
Interfering with leukocyte trafficking in Crohn's disease, PMID: 31327399
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts, PMID: 30165490
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease, PMID: 29767705
Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions, PMID: 28147349
Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects, PMID: 28804488
Current and emerging biologics for ulcerative colitis, PMID: 25547087
Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis, PMID: 25761174
Emerging treatments for ulcerative colitis: a systematic review, PMID: 28503977
Advances in the development of new biologics in inflammatory bowel disease, PMID: 27366024
Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies, PMID: 31843275
Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial, PMID: 32464142
The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews, PMID: 27306074
Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases, PMID: 25110260
Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis, PMID: 31108158
Review article: anti-adhesion therapies for inflammatory bowel disease, PMID: 24479980
The future of inflammatory bowel disease therapy: where do we go from here?, PMID: 23295705
Antibodies to watch in 2018, PMID: 29300693
Factors Impacting the Immunogenicity of Etrolizumab & Clinical Consequences., PMID:40481373
Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease., PMID:40401357
Gut-directed therapeutics in inflammatory bowel disease., PMID:40305008
Pharmacokinetic analysis using single dilution assays: enhancing precision, reducing errors and increasing throughput., PMID:39783800
Vagal innervation limits brain injury by inhibiting gut-selective integrin-mediated intestinal immunocyte migration in intracerebral hemorrhage., PMID:39659582
Ulcerative Colitis Severity Classification and Localized Extent (UC-SCALE): An Artificial Intelligence Scoring System for a Spatial Assessment of Disease Severity in Ulcerative Colitis., PMID:39657580
Efficacy and Safety of Etrolizumab in the Treatment of Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:39292841
Evaluation of low volume sampling devices for a pharmacodynamic biomarker analysis: Challenges and solutions., PMID:39217703
Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis., PMID:39193512
[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins]., PMID:39176460
Meta-analysis of etrolizumab versus placebo in ulcerative colitis: safety and efficacy outcomes., PMID:38855341
Gut Microbial Species and Endotypes Associate with Remission in Ulcerative Colitis Patients Treated with Anti-TNF or Anti-integrin Therapy., PMID:38836628
Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis., PMID:38736478
Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules., PMID:38671563
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials., PMID:38572328
Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells., PMID:38310086
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis: a protocol of systematic review and meta-analysis of placebo-controlled, randomised clinical trials., PMID:38267240
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis., PMID:38185396
Validation of low-volume sampling devices for pharmacokinetic analysis: technical and logistical challenges and solutions., PMID:37855111
Machine Learning-Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials., PMID:37828747
A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score., PMID:37718498
Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing., PMID:37029786
The Underappreciated Role of Secretory IgA in IBD., PMID:36943800
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial., PMID:36240801
The Memory T Cell "Communication Web" in Context with Gastrointestinal Disorders-How Memory T Cells Affect Their Surroundings and How They Are Influenced by It., PMID:36139354
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis., PMID:35851998
Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells., PMID:35815779
Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis., PMID:35789549
Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis., PMID:35543875
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial., PMID:35366308
Review article: emerging drug therapies in inflammatory bowel disease., PMID:35166398
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease., PMID:35165437
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis., PMID:34856198
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial., PMID:34849918
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial., PMID:34798039
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study., PMID:34798038
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study., PMID:34798037
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials., PMID:34798036
Etrolizumab for ulcerative colitis: beyond what meets the eye., PMID:34798035
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis., PMID:34797516
Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics., PMID:34686510
Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease., PMID:34467254
Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives., PMID:34466013
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents., PMID:34449288
Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers., PMID:33778929
An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers., PMID:33778928
Training and deploying a deep learning model for endoscopic severity grading in ulcerative colitis using multicenter clinical trial data., PMID:33718871
Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More., PMID:32570252
Impact of various central endoscopy reading models on treatment outcome in Crohn's disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial., PMID:32464142
Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program., PMID:32445184
-αEβ7(CD103-ITGAE+ITGB7)-antibodysystem.jpg)
For research use only. Not for human or drug use.
